Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Summary

The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).

Timeline

Start

2009-06

Primary completion

2009-09

Completion

2009-09

Outcome

Met primary endpoint

registry Oxymorphone ER 30 mg vs Oxycodone CR 60 mg; p <0.001; Least Square Means Difference -28.8 (95% CI -41.6 to -16.0) NCT00955110 ↗

registry Oxymorphone ER 15 mg vs Oxycodone CR 30 mg; p <0.001; Least Square Mean Difference -50.5 (95% CI -63.4 to -37.5) NCT00955110 ↗

Publications

• Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. Pain Physician. 2010 Nov-Dec;13(6):561-73.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Oxycodone	Other / unclassified	30 mg	Oral
Comparator	Oxycodone	Other / unclassified	60 mg	Oral
Subject	Oxymorphone	Small molecule	15 mg	Oral
Subject	Oxymorphone	Small molecule	30 mg	Oral
Background	Hydromorphone	Other / unclassified	8 mg	—

Indications

No indication recorded.